

Global Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

<https://marketpublishers.com/r/G6042BF1CC1EN.html>

Date: March 2018

Pages: 741

Price: US\$ 4,200.00 (Single User License)

ID: G6042BF1CC1EN

Abstracts

Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for global injectable drug delivery market are listed below:

Baxter International, Inc.,

Becton Dickinson and Company,

Gerresheimer AG,

Pfizer, Inc.,

Schott AG,

Alkermes Plc.,

Eli Lilly and Company,

Sandoz,

Terumo Corporation,

Teva Pharmaceuticals Industries Ltd.

Ypsomed,

Bespak

The market is further segmented into:

Type

Usage Pattern

End-User

Mode of Administration

Distribution Channel

Application

Geography

The global injectable drug delivery market is segmented on of type, portability, type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The global injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 75.7% market share in 2018, growing at a CAGR of 12.4% and will cross USD 837,873.64 million by 2025

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 50.1% market share in 2018, growing at a CAGR of 12.1% and will cross USD 540,977.35 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 13.6% in the forecast period, and is expected to reach USD 265,145.17 million in 2025 from USD 82,915.00 million in 2017

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 93.2% market share in 2018, growing at a CAGR of 12.5% and will cross USD 1,036,829.49 million by 2025.

On the basis of mode of administration, the market is segmented into skin, circulatory/musculoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 46.8% market share in 2018, growing at a CAGR of 12.8% and will cross USD 532,193.0 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 62.6% market share in 2018, growing at a CAGR of 12.5% and will cross USD 693,323.05 million by 2025.

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 69.2% market share in 2018, growing at a CAGR of 12.7% and will cross USD 780,682.75 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 13.5% in the forecast period, and is expected to reach USD 142,617.48 million in 2025 from USD 44,812.56 million in 2017

Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The

geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Based on geography, the Global injectable drug delivery market is segmented into geographical regions, such as,

North- America

South America

Europe

Asia-Pacific

Middle East and Africa

Covered in this report

The report covers the present scenario and the growth prospects of the global injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Contents

1 INTRODUCTION

- 1.1 Overview Of Global Injectable Drug Delivery Market
- 1.2 Currency And Pricing
- 1.3 Limitation
- 1.4 Markets Covered

2 MARKET SEGMENTATION

- 2.1 Markets Covered
- 2.2 Geographic Scope
- 2.3 Years Considered For The Study
- 2.4 Currency And Pricing
- 2.5 Research Methodology
- 2.6 Primary Interviews With Key Opinion Leaders
- 2.7 Secondary Sources
- 2.8 Assumptions

3 MARKET OVERVIEW

- 3.1 Drivers
 - 3.1.1 Rising Cases Of Chronic Diseases
 - 3.1.2 Rising Demand Of Self-Injection Devices
 - 3.1.3 Growth Of Biologics Market
 - 3.1.4 Technological Advancements And Innovations In Drug Delivery Market
- 3.2 Restraints
 - 3.2.1 Needlestick Injuries And Infections
 - 3.2.2 High Cost Of Development
 - 3.2.3 Strict Regulatory Framework
- 3.3 Opportunity
 - 3.3.1 Increasing Demand For Generic And Biosimilar Drugs
 - 3.3.1.1 Generics
 - 3.3.1.2 Biosimilars
 - 3.3.2 Increasing Demand For Contraceptive Injectables
 - 3.3.3 Increasing Demand For Self-Administration Of Drugs
- 3.4 Challenges
 - 3.4.1 Alternative Route Of Drug Administration

- 3.4.2 Product Recall
- 3.4.3 Stability Of Products
- 3.4.4 Sterility Of Injections

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE

6.1 Overview

6.2 Injectable Drug Delivery Devices

6.2.1 Conventional Injection Devices

6.2.1.1 Conventional Injection Devices, By Material

6.2.1.1.1 Glass

6.2.1.1.2 Plastic

6.2.1.2 Conventional Injection Devices, By Product

6.2.1.2.1 Fillable Syringes

6.2.1.2.2 Prefilled Syringes

6.2.1.3 Conventional Injection Devices, By Usability

6.2.1.3.1 Reusable Syringes

6.2.1.3.2 Disposable Syringes

6.2.2 Self Injection Devices

6.2.2.1 Needle Free Injectors (Nfi)

6.2.2.2 Needle Free Injectors, By Product

6.2.2.2.1 Fillable Needle-Free Injectors

6.2.2.2.2 Prefilled Needle-Free Injectors

6.2.2.3 Needle Free Injectors, By Technology

6.2.2.3.1 Jet Based Needle Free Injectors:

6.2.2.3.2 Spring Based Needle Free Injectors:

6.2.2.3.3 Laser Based Needle Free Injectors:

6.2.2.3.4 Vibration Based Needle Free Injectors:

6.2.2.4 Needle Free Injectors, By Usability

6.2.2.4.1 Reusable Needle-Free Injectors

6.2.2.4.2 Disposable Needle-Free Injectors

6.2.2.5 Auto Injectors

6.2.2.6 Auto Injectors, By Product

6.2.2.6.1 Fillable Auto Injectors

6.2.2.6.2 Pre-Filled Autoinjectors

- 6.2.2.7 Auto Injectors, By Technology
 - 6.2.2.7.1 Automated Auto Injectors
 - 6.2.2.7.2 Manual Auto Injectors
- 6.2.2.8 Auto Injectors, By Design
 - 6.2.2.8.1 Standardized Auto Injectors
 - 6.2.2.8.2 Automated Autoinjectors
- 6.2.2.9 Auto Injectors, By Usability
 - 6.2.2.9.1 Reusable Autoinjectors
 - 6.2.2.9.2 Disposable Autoinjectors
- 6.2.2.10 Pen Injectors
- 6.2.2.11 Pen Injectors, By Product
 - 6.2.2.11.1 Single Chambered Pen Injectors
 - 6.2.2.11.2 Dual Chambered Pen Injectors
- 6.2.2.12 Pen Injectors, By Design
 - 6.2.2.12.1 Standard Pen Injectors
 - 6.2.2.12.2 Customized Pen Injectors
- 6.2.2.13 Pen Injectors, By Usability
 - 6.2.2.13.1 Reusable Pen Injectors
 - 6.2.2.13.2 Disposable Pen Injectors
- 6.2.2.14 Wearable Injectors
 - 6.2.2.14.1 Other Devices
- 6.3 Injectable Drug Delivery Formulation
 - 6.3.1 Conventional Drug Delivery Formulations
 - 6.3.1.1 Solutions
 - 6.3.1.2 Reconstituted/Lyophilized Formulations
 - 6.3.1.3 Suspensions
 - 6.3.1.4 Emulsions
 - 6.3.2 Novel Drug Delivery Formulations
 - 6.3.2.1 Colloidal Dispersions
 - 6.3.2.1.1 Niosomes
 - 6.3.2.1.2 Liposomes
 - 6.3.2.1.3 Polymeric Mixed Micelles
 - 6.3.2.1.4 Nanoparticles
 - 6.3.2.1.5 Nanosuspensions
 - 6.3.2.1.6 Nanoemulsions/Microemulsions
 - 6.3.2.1.7 Solid Lipid Nanoparticles
 - 6.3.2.2 Microparticles
 - 6.3.2.2.1 Microspheres
 - 6.3.2.2.2 Microcapsules

6.3.2.3 Long Acting Injection Formulation

7 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

7.1 Overview

7.2 Global Injectable Drug Delivery Market, By Application

7.3 Hormonal Disorders

7.3.1 Injectable Drugs For Diabetes

7.3.2 Injectable Drugs For Anemia

7.3.3 Injectable Drugs For Reproductive Health Disease

7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy

7.3.5 Injectable Drugs For Osteoporosis

7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd)

7.4 Oncology

7.5 Autoimmune Diseases

7.5.1 Injectable Drugs For Rheumatoid Arthritis

7.5.2 Injectable Drugs For Multiple Sclerosis

7.5.3 Injectable Drugs For Crohn'S Diseases

7.5.4 Injectable Drugs For Psoriasis

7.5.5 Injectable Drugs For Other Autoimmune Diseases

7.6 Orphan Disease

7.7 Other Applications

7.7.1 Injectable Drugs For Pain Management

7.7.2 Injectable Drugs For Allergy Treatment

7.7.3 Injectable Drugs For Aesthetic Treatments

7.7.4 Injectable Drugs For Hepatitis C

7.7.5 Injectable Drugs For Hemophilia

8 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

8.1 Overview

8.2 Curative Care

8.3 Immunizations

8.4 Other Usage Pattern

9 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

9.1 Overview

- 9.2 Skin
- 9.3 Circulatory/ Muskoskeletal
- 9.4 Organs
- 9.5 Central Nervous System

10 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER

- 10.1 Overview
- 10.2 Hospitals And Clinics
- 10.3 Home Healthcare Settings
- 10.4 Research Laboratories
- 10.5 Pharmaceutical And Biotechnological Companies
- 10.6 Other End Users

11 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

- 11.1 Overview
 - 11.1.1 Hospital Pharmacy
 - 11.1.2 Pharmacy Stores
 - 11.1.3 Direct Tender
 - 11.1.4 Online Pharmacy

12 GLOBAL INJECTABLE DRUG DILIVERY MARKET BY GEOGRAPHY

- 12.1 Overview
- 12.2 North America
 - 12.2.1 U.S.
 - 12.2.2 Canada
 - 12.2.3 Mexico
- 12.3 Europe
 - 12.3.1 Germany
 - 12.3.2 France
 - 12.3.3 U.K.
 - 12.3.4 Italy
 - 12.3.5 Switzerland
 - 12.3.6 Spain
 - 12.3.7 Netherland
 - 12.3.8 Russia

- 12.3.9 Turkey
- 12.3.10 Belgium
- 12.3.11 Rest Of Europe
- 12.4 Asia-Pacific
 - 12.4.1 Japan
 - 12.4.2 China
 - 12.4.3 India
 - 12.4.4 South Korea
 - 12.4.5 Australia
 - 12.4.6 Thailand
 - 12.4.7 Malaysia Injectable Drug Delivery Market
 - 12.4.8 Singapore
 - 12.4.9 Indonesia
 - 12.4.10 Phillippines
 - 12.4.11 Rest Of Asia-Pacific Injectable Drug Delivery Market
- 12.5 South America
 - 12.5.1 Brazil
 - 12.5.2 Rest Of South Africa
- 12.6 Middle East & Africa
 - 12.6.1 South Africa Injectable Drug Delivery Market
 - 12.6.2 Rest Of Middle East& Africa Injectable Drug Delivery Market

13 GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE

- 13.1 Company Share Analysis: Global

14 COMPANY PROFILES

- 14.1 Becton, Dickinson And Company
 - 14.1.1 Company Overview
 - 14.1.1.1 Drivers Explained
 - 14.1.1.2 Weaknesses Explained
 - 14.1.1.3 Oppurtunities Explained
 - 14.1.1.4 Threats Explained
 - 14.1.2 Becton, Dickinson And Company: Revenue Analysis
 - 14.1.3 Product Portfolio
 - 14.1.4 Recent Developments
- 14.2 Pfizer
 - 14.2.1 Company Overview

- 14.2.1.1 Drivers Explained
- 14.2.1.2 Weaknesses Explained
- 14.2.1.3 Oppurtunities Explained
- 14.2.1.4 Threats Explained
- 14.2.2 Pfizer, Inc.: Revenue Analysis
- 14.2.3 Product Portfolio
- 14.2.4 Recent Developments
- 14.3 Baxter International, Inc.
 - 14.3.1 Company Overview
 - 14.3.1.1 Drivers Explained
 - 14.3.1.2 Weaknesses Explained
 - 14.3.1.3 Oppurtunities Explained
 - 14.3.1.4 Threats Explained
 - 14.3.2 Baxter International: Revenue Analysis
 - 14.3.3 Product Portfolio
 - 14.3.4 Recent Developments
- 14.4 Gerresheimer Ag
 - 14.4.1 Company Overview
 - 14.4.2 Gerresheimer Ag: Revenue Analysis
 - 14.4.3 Product Portfolio
 - 14.4.4 Recent Developments
- 14.5 Schott Ag Inc.
 - 14.5.1 Company Overview
 - 14.5.2 Schott Ag Inc: Revenue Analysis
 - 14.5.3 Product Portfolio
 - 14.5.4 Recent Developments
- 14.6 Alkermes Inc.
 - 14.6.1 Company Overview
 - 14.6.2 Alkermes Inc.: Revenue Analysis
 - 14.6.3 Product Portfolio
 - 14.6.4 Recent Developments
- 14.7 Antares Pharma
 - 14.7.1 Company Overview
 - 14.7.2 Antares Pharma: Revenue Analysis
 - 14.7.3 Product Portfolio
 - 14.7.4 Recent Developments
- 14.8 Bepak (Subsidiary Of Consort Medical Company)
 - 14.8.1 Company Overview
 - 14.8.2 Bepak (Subsidiary Of Consort Medical Company): Revenue Analysis

- 14.8.3 Product Portfolio
- 14.8.4 Recent Developments
- 14.9 Elcam Medical
 - 14.9.1 Company Overview
 - 14.9.2 Elcam Medical: Company Snapshot
 - 14.9.3 Product Portfolio
 - 14.9.4 Recent Developments
- 14.10 Eli Lilly And Company
 - 14.10.1 Company Overview
 - 14.10.1.1 Drivers Explained
 - 14.10.1.2 Weaknesses Explained
 - 14.10.1.3 Oppurtunities Explained
 - 14.10.1.4 Threats Explained
 - 14.10.2 Eli Lilly And Company: Revenue Analysis
 - 14.10.3 Product Portfolio
 - 14.10.4 Recent Developments
- 14.11 Haselmeier
 - 14.11.1 Company Overview
 - 14.11.2 Haselmeier: Company Snapshot
 - 14.11.3 Product Portfolio
 - 14.11.4 Recent Developments
- 14.12 Mylan N.V.
 - 14.12.1 Company Overview
 - 14.12.2 Mylan N.V.: Revenue Analysis
 - 14.12.3 Product Portfolio
 - 14.12.4 Recent Developments
- 14.13 Novo Nordisk
 - 14.13.1 Company Overview
 - 14.13.2 Novo Nordisk: Revenue Analysis
 - 14.13.3 Product Portfolio
 - 14.13.4 Recent Developments
- 14.14 Owen Mumford Ltd
 - 14.14.1 Company Overview
 - 14.14.2 Owen Mumford Ltd: Company Snapshot
 - 14.14.3 Product Portfolio
 - 14.14.4 Recent Developments
- 14.15 Sandoz International Gmbh
 - 14.15.1 Company Overview
 - 14.15.2 Sandoz International Gmbh: Revenue Analysis

- 14.15.3 Product Portfolio
- 14.15.4 Recent Developments
- 14.16 Sanofi
 - 14.16.1 Company Overview
 - 14.16.2 Sanofi: Revenue Analysis
 - 14.16.3 Product Portfolio
 - 14.16.4 Recent Developments
- 14.17 Terumo Corporation
 - 14.17.1 Company Overview
 - 14.17.2 Terumo Corporation: Revenue Analysis
 - 14.17.3 Product Portfolio
 - 14.17.4 Recent Developments
- 14.18 Teva Pharmaceutical
 - 14.18.1 Company Overview
 - 14.18.1.1 Drivers Explained
 - 14.18.1.2 Weaknesses Explained
 - 14.18.1.3 Oppurtunities Explained
 - 14.18.1.4 Threats Explained
 - 14.18.2 Teva Pharmaceutical: Revenue Analysis
 - 14.18.3 Product Portfolio
 - 14.18.4 Recent Developments
- 14.19 West Pharmaceutical Services, Inc
 - 14.19.1 Company Overview
 - 14.19.2 West Pharmaceutical Services, Inc: Revenue Analysis
 - 14.19.3 Product Portfolio
 - 14.19.4 Recent Developments
- 14.20 Ypsomed Holding Ag
 - 14.20.1 Company Overview
 - 14.20.2 Ypsomed Holding Ag: Revenue Analysis
 - 14.20.3 Product Portfolio
 - 14.20.4 Recent Developments

15 RELATED REPORTS

List Of Figures

LIST OF FIGURES

Figure 1 Global Injectable Drug Delivery Market: Segmentation

Figure 2 Global Injectable Drug Delivery Market: Geographic Scope

Figure 3 Global Injectable Drug Delivery Market: Data Triangulation

Figure 4 Global Injectable Drug Delivery Market: Research Snapshot

Figure 5 Global Injectable Drug Delivery Market: Bottom Up Approach

Figure 6 Global Injectable Drug Delivery Market: Top Down Approach

Figure 7 Global Injectable Drug Delivery Market: Interview Demographics

Figure 8 Figure: Drivers, Restraints, Opportunities And Challenges Of The Injectable Drug Delivery Market

Figure 9 Number Of Needlestick Injuries

Figure 10 North America Is Expected To Dominate The Market For Injectable Drug Delivery In 2017 And Apac Is Expected To Be Growing With The Highest Cagr In The Forecast Period To 2025

Figure 11 Technological Development And Increasing Prevalence Of Chronic Diseases Are Expected To Drive The Market For Injectable Drug Delivery In The Forecast Period 2018 To 2025

Figure 12 Injectable Drug Delivery Formulation Market Segment Is Expected To Account For The Largest Share Of The Global Injectable Drug Delivery Market In 2018 & 2025

Figure 13 North America Is The Highest Growing And Most Profitable Revenue Pockets For Injectable Drug Delivery Manufacturers In The Forecast Period To 2018 To 2025

Figure 14 Global Injectable Drug Delivery Market: By Type, Snapshot 2017

Figure 15 Global Injectable Drug Delivery Market: By Application, Snapshot 2017

Figure 16 Global Injectable Drug Delivery Market: By Usage Pattern, Snapshot 2017

Figure 17 Global Injectable Drug Delivery Market: By Mode Of Administration, Snapshot 2017

Figure 18 Global Injectable Drug Delivery Market Dominated By Hospital And Clinics Segment

Figure 19 Global Injectable Drug Deliverymarket: By End-User, Snapshot 2017

Figure 20 Global Injectable Drug Delivery Market: By Distribution Channel, Snapshot 2017

Figure 21 North America Injectable Drug Delivery Market Snapshot (2017)

Figure 22 Europe Injectable Drug Delivery Market Snapshot (2017)

Figure 23 Asia-Pacific Injectable Drug Delivery Market Snapshot (2017)

Figure 24 South America Injectable Drug Delivery Market Snapshot (2017)

Figure 25 Middle East And Africa Injectable Drug Delivery Market Snapshot (2017)

Figure 26 Global Injectable Drug Delivery Market: Company Share 2017 (%)

Figure 27 Becton, Dickinson And Company: Swot (Strength, Weakness, Opportunities And Threats)

Figure 28 Pfizer, Inc.: Swot (Strength, Weakness, Opportunities And Threats)

Figure 29 Baxter International Inc.: Swot (Strength, Weakness, Opportunities And Threats)

Figure 30 Eli Lilly And Company: Swot (Strength, Weakness, Opportunities And Threats)

Figure 31 Teva Pharmaceutical: Swot (Strength, Weakness, Opportunities And Threats)

I would like to order

Product name: Global Injectable Drug Delivery Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Product link: <https://marketpublishers.com/r/G6042BF1CC1EN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6042BF1CC1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

